dorsaVi secures elite sport and European clinical partnerships worth over A$200,000
dorsaVi Limited (ASX: DVL) has announced two commercial agreements that demonstrate the dorsaVi Ultra-Edge Intelligence Expansion strategy is attracting credibility-conferring partners across elite sport and clinical research. ESPN’s Resident Injury Expert Dr Chirag Patel and the European SEROMA clinical consortium have both selected dorsaVi’s wearable sensor technology following competitive review processes, with combined contracted revenue exceeding A$200,000.
Both agreements are underpinned by dorsaVi’s proprietary Onboard Sensor Processing (OSP) capability, which transforms the company’s wearable sensors from passive data collection devices into real-time intelligent systems capable of generating validated, clinical-grade metrics at the point of measurement. Management believes these engagements open materially larger addressable markets across pharmaceutical trials, occupational health, defence, and emerging robotics applications.
The company’s Select Medical Network has surpassed 100 active sites across the United States, with ViMove+ now integrated onto the Select Hub platform. Trials with additional franchise physiotherapy groups have commenced across the US East Coast, reinforcing the platform’s clinical utility and structured conversion pathways.
When big ASX news breaks, our subscribers know first
What is Onboard Sensor Processing and why does it matter?
Traditional wearable devices capture raw biomechanical data and transmit it to cloud infrastructure for processing. The resulting latency makes real-time intervention impossible in elite sport and remote clinical applications, limiting clinical utility in fast-moving research environments.
dorsaVi’s Onboard Sensor Processing (OSP) architecture solves this fundamentally. Data capture, analysis, and interpretation occur directly on the sensor device, enabling immediate transmission of refined, clinically meaningful metrics at the point of measurement. Rather than shipping raw data streams to external servers, the sensor itself performs AI-powered inference and delivers actionable insights in real time.
For investors, OSP represents the technological moat that won both the Dr Patel and SEROMA contracts. It positions dorsaVi ahead of passive data collection competitors and underpins scalability across multiple high-value markets where real-time decision-making is critical.
Dr Chirag Patel partnership targets elite sport and military markets
dorsaVi has formalised commercial terms with Dr Chirag Patel for an 8-month project to develop a premium lower-limb analytics module within the ViMove+ platform. Dr Patel is Managing Director of New Horizons Foot and Ankle Associates, Founder/CEO of Health AnalySYST, and Resident Injury Expert for ESPN. His practice services elite athletes from across the NFL, NBA, MLB, MLS, and USL, whilst the ESPN platform reaches millions of viewers on injury prevention and return-to-play topics.
The project builds directly on successful research completed in early 2025, which identified optimal sensor positioning on the lower limb for superior algorithmic outputs. The new phase moves from research to commercial product, capturing real-time biomechanical data on athletes during training and competition. Target applications include NCAA, elite sport, and military use cases, with revenue targeting 2026.
A collaboration with a physician of Dr Patel’s stature validates dorsaVi’s technology in a highly visible context. This creates a halo effect that management expects will accelerate conversations with other sporting bodies, military procurement teams, and adjacent clinical markets. Foot and ankle biomechanics are among the most data-rich domains in human movement, with the sensor data captured in this project (joint angles, load asymmetry, gait patterns, movement efficiency) precisely the structured, high-resolution datasets attracting intense interest from humanoid robotics developers seeking to train and validate locomotion models.
Mat Regan, Group CEO of dorsaVi
“Dr Patel is a clinician with a national media platform and relationships across elite US professional sport. The SEROMA consortium represents scientific leadership within a global disease community, with direct connections to pharmaceutical companies and regulatory bodies. Both selected dorsaVi following competitive processes, which we believe reflects the strength of our technology and platform.”
SEROMA consortium selects dorsaVi for landmark European axSpA study
Axial Spondyloarthritis (axSpA) is a chronic, progressive inflammatory condition causing pain, stiffness, and loss of spinal function. Despite affecting millions globally, the condition has lacked a reliable, objective clinical measure of disease progression. The current standard, the BASMI index, has recently been downgraded in the ASAS-OMERACT Core Outcome Set due to poor reliability and limited sensitivity.
dorsaVi’s sensors and ViMove+ software have been selected, following a competitive review, as the technology platform for the SEROMA project, a landmark European clinical study designed to replace BASMI with a validated, sensor-based alternative. The SEROMA consortium brings together leading European rheumatologists across six clinical sites, with direct involvement of the Assessment of Spondyloarthritis International Society (ASAS), a body representing over 200 axSpA researchers globally. Three global pharmaceutical companies are already engaged, recognising that validated, sensor-based outcome measures are urgently needed for drug approval trials under FDA and EMA frameworks.
dorsaVi was selected for its proven expertise in clinical sensor technology, strong intellectual property, affordable and collaborative business model, and track record of innovation enabling expansion into whole-spine assessment protocols. Once validated, the SEROMA sensor-based outcome measure is expected to be rapidly adopted in global pharmaceutical trials, creating recurring revenue through licensing, service agreements, and platform subscriptions. Beyond pharma, the validated methodology extends across rheumatology and other musculoskeletal conditions, multiplying the addressable market.
| Phase | Milestone | Commercial Outcome |
|---|---|---|
| 1 | Regulatory endorsement via ASAS | Replaces BASMI as gold standard |
| 2 | Pharma integration into pivotal drug trials | Recurring licensing/service revenue |
| 3 | Extension across rheumatology/MSK diseases | Multiplied addressable market |
The selection of dorsaVi by a leading European clinical consortium is well-timed. Europe is establishing new regulatory frameworks governing AI and autonomous systems in healthcare and robotics, frameworks that place a premium on validated, clinically-anchored sensor technology. dorsaVi’s participation in landmark studies like SEROMA builds the regulatory track record and European clinical network that will be essential for accessing this growing market.
Select Medical Network momentum continues
The Select Medical physiotherapy network has now surpassed 100 active sites across the United States, with targeted expansion into additional US states underway. ViMove+ has been integrated directly onto the Select Hub platform, streamlining deployment and deepening the clinical workflow integration that has driven adoption to date.
Key developments include:
- 100+ active sites across the United States
- New US states targeted for expansion
- ViMove+ live on Select Hub platform
- East Coast franchise trials ongoing
Management views the East Coast trial activity as a meaningful pipeline development channel, with structured conversion pathways into the Select model. Early engagement data is reinforcing the platform’s clinical utility and the willingness of physiotherapy practices to adopt objective, sensor-based movement assessment as part of routine care.
Semiconductor roadmap enhances OSP capability
dorsaVi’s investment in neuromorphic computing and Resistive RAM (RRAM), advanced through the January 2026 collaboration with ITRI (Taiwan) and NTU (Singapore) to the 22-nm technology node, is directly relevant to the commercial pipeline being built today. Both Dr Patel’s elite sport clients and the SEROMA pharma partners are prospective beneficiaries of the step-change in OSP performance these technologies will enable.
Neuromorphic processing, inspired by the architecture of the human brain, is exceptionally well-suited to the pattern-recognition and time-series analysis demands of continuous biomechanical monitoring. RRAM provides ultra-low power, high-speed memory access that makes on-device AI inference feasible in a wearable form factor. The 22-nm programme targets compute-in-memory efficiency exceeding 20 TOPS/W, a capability that will materially extend what dorsaVi’s sensors can detect and report in real time.
This is not speculative research and development. The semiconductor roadmap directly enhances the OSP capability that won both current commercial deals and positions dorsaVi to serve markets that currently lack adequate solutions, including continuous remote patient monitoring, precision medicine trials, elite sports analytics, and industrial occupational health.
Robotics data opportunity positions dorsaVi for emerging market
Beyond the clinical and sporting markets, dorsaVi’s leadership has identified a longer-horizon opportunity in the role of high-quality human movement data in the development of humanoid robotics. The global humanoid robotics sector is scaling rapidly, with the broader robotics market projected to reach US$372.59 billion by 2034. A critical bottleneck is the availability of validated, high-resolution biomechanical data, particularly for complex movements such as foot and ankle articulation, spinal flexion, and multi-joint coordination under load.
dorsaVi’s clinical-grade sensor data, validated against the gold-standard Vicon system to within 1-2 degrees, is precisely the structured movement dataset that robotics developers require to train, test, and refine locomotion models. The foot and ankle metrics being developed with Dr Patel, and the spinal mobility data captured in SEROMA, represent sensor data categories of direct relevance to next-generation robotic systems.
European regulatory developments, including emerging frameworks governing AI in healthcare and autonomous robotic systems, further underpin the value of dorsaVi’s position as a provider of validated, clinically-anchored sensor technology. The company’s participation in European clinical research through SEROMA establishes exactly the kind of regulatory track record these frameworks will require.
| Elite Sport (Dr Patel) | Clinical Research (SEROMA) |
|---|---|
| Biomechanical alerts during competition | Validated spinal mobility metrics at point of assessment |
| Real-time fatigue markers and valgus collapse detection | No cloud dependency — scalable across dispersed trial sites |
| Proactive injury prevention | Continuous, objective metrics for drug efficacy trials |
The next major ASX story will hit our subscribers first
Investment case strengthens across multiple fronts
The announcements represent a meaningful acceleration in dorsaVi’s commercial trajectory and technology leadership. Technology validated in elite sport and clinical research opens pathways to pharma, occupational health, defence, and robotics.
- Revenue milestone: >A$200,000 contracted across two agreements
- Network scale: Select at 100+ sites with expansion underway
- Clinical credibility: ESPN-platform physician and European consortium validation
- Technology moat: OSP delivers real-time on-device AI inference
- Semiconductor roadmap: 22-nm RRAM/neuromorphic programme targeting >20 TOPS/W
- Adjacent markets: Foot/ankle and spinal data relevant to humanoid robotics
Mat Regan, Group CEO of dorsaVi
“Our RRAM and neuromorphic investments represent the natural extension of the OSP capability that is already attracting these clients. As we look further ahead, we see a world where the data our sensors generate today (foot angles, spine vectors and movement signatures) becomes foundational to the next generation of robotics and intelligent physical systems. Our focus is on building toward that future whilst continuing to deliver commercial outcomes today.”
dorsaVi has demonstrated technology leadership, attracted credibility-conferring partners, and positioned itself for recurring revenue across expanding addressable markets. The dorsaVi Ultra-Edge Intelligence Expansion strategy is attracting exactly the type of high-credibility, high-potential partners management anticipated, with the OSP capability serving as the technological foundation for commercial growth across clinical, sport, pharmaceutical, and emerging robotics applications.
Get Healthcare Tech News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX healthcare announcements delivered within minutes, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start getting market-moving news the moment it breaks, with expert coverage already done for you.